O

nly three types of drug-resistant bacteria make the Center for Disease Control and Prevention’s list of  “urgent” threats. One of them is gonorrhea.

That particular sexually transmitted infection is the target of a new drug being developed by Entasis, an antibiotics-focused spin-off from pharma giant AstraZeneca. But they’re getting help: their nonprofit partner, the Global Antibiotic Research and Development Partnership, will be funding the next round of trials and doing studies to ensure this drug keeps working for as long as possible. The partnership is GARDP’s first.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Before penicillin, when heavy metals were used to treat clap we used to say “One night with Venus, a lifetime with Mercury”. Better advice, keep it in your knickers until you get through sex ed 101.

  • It is interesting news as many drug resistant bacteria are immerging.So a step in this research will open door for other MDR organisms.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X